Using perinatal tissue allografts to heal diabetic foot ulcers

A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating the Efficacy of Multiple Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Treatment of Nonhealing Diabetic Foot Ulcers.

This study is testing if adding special tissue from newborns to regular care can help heal diabetic foot ulcers faster and better than just using standard care alone.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 170 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Samaritan Biologics (industry)
• Drugs / interventions: chemotherapy, Prednisone
• Locations: 1 site (Monroe, North Carolina)
• Trial ID: NCT06437028 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate whether the application of perinatal tissue allografts, in addition to standard wound care, can enhance the healing of chronic diabetic foot ulcers. Participants will have one ulcer treated with weekly applications of the allografts alongside standard care, while the other ulcer will receive standard care alone. The study will track healing progress through weekly measurements and photographs over a 12-week period, as well as assess the impact on participants' quality of life through questionnaires. The goal is to determine if the allografts lead to a higher rate of complete ulcer closure compared to standard care alone.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with type 1 or 2 diabetes and chronic foot ulcers that meet specific size and duration criteria.

Not a fit: Patients with ulcers that do not meet the study's size, duration, or grade criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly improve healing rates for patients with chronic diabetic foot ulcers.

How similar studies have performed: Previous studies have shown promise in using advanced wound therapies like perinatal tissue allografts for similar conditions, suggesting potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

Potential subjects are required to meet all the following criteria for enrollment in the study.

1. Subjects must be at least 18 years of age or older.
2. Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus.
3. At randomization subjects must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement.
4. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care, prior to the initial screening visit.
5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.
6. The target ulcer must be Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.
7. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:

   1. ABI between 0.7 and ≤ 1.3;
   2. TBI ≥ 0.6;
   3. TCOM ≥ 40 mmHg;
   4. PVR: biphasic.
8. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to enrollment.
10. The potential subject must consent to using the prescribed offloading method for the duration of the study.
11. The potential subject must agree to attend the weekly study visits required by the protocol.
12. The potential subject must be willing and able to participate in the informed consent process.

Exclusion Criteria:

Potential subjects meeting any of the following criteria will be excluded from enrollment in the study.

1. A subject known to have a life expectancy of \< 6 months is excluded.
2. The subject is excluded if the target ulcer is not secondary to diabetes.
3. If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded.
4. If there is evidence of osteomyelitis complicating the target ulcer, the subject is excluded.
5. A potential subject cannot have an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
6. A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded.
7. The topical application of steroids to the ulcer surface within one month of initial screening is not permitted.
8. A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer.
9. The subject is excluded if the surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Photographic planimetry is not required for measurements taken during the historical run-in period (e.g. calculating surface area using length x width is acceptable).
10. The subject is excluded if the surface area measurement of the Target ulcer decreases by 20% or more during the 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1/randomization visit, during which time the subject received SOC.
11. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
12. A subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer is excluded.
13. Women who are pregnant or considering becoming pregnant within the next 6 months are excluded.
14. A potential subject with end stage renal disease requiring dialysis is excluded.
15. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.
16. A subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments is excluded.
17. A Subject treated with hyperbaric oxygen therapy or a Cellular Acellular, or Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit is excluded.
18. A subject is excluded if they are malnourished: a score of less than 17 on the Mini Nutritional Assessment (MNA).

Where this trial is running

Monroe, North Carolina

• Monroe Biomedical Research — Monroe, North Carolina, United States (RECRUITING)

Study contacts

• Principal investigator: Thomas E Serena, MD — SerenaGroup, Inc.
• Study coordinator: Jeremy J Mercuri, PhD

Conditions: Diabetic Foot Ulcer, Diabetes, Diabetic Foot, Allograft, Amnion, Chorion, Wound healing, Advanced wound care